Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects

G. Carosi; A. Lazzarin; H. Stellbrink; G. Moyle; S. Rugina; S. Staszewski; N. Givens; L. Ross; C. Granier; M. Ait-Khaled; D. Leather; W. G. Nichols

doi:10.1310/hct1006-356

Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects

G. Carosi, A. Lazzarin, H. Stellbrink, G. Moyle, S. Rugina, S. Staszewski, N. Givens, L. Ross, C. Granier, M. Ait-Khaled, D. Leather, W. G. Nichols

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: Fosamprenavir/ritonavir 1400 mg/100 mg once-daily regimen may have a more favourable tolerability and lipid profile than the fosamprenavir/ ritonavir twice-daily regimen, while maintaining comparable antiviral efficacy. Methods: This open-label study had a group-sequential design with a stage 1 Week 24 futility analysis, with both efficacy and safety go-criteria for progression to stage 2. There were 214 antiretroviral-naive, HIV-1-infected subjects who were randomised to receive either fosamprenavir/ritonavir 1400 mg/100 mg once daily or fosamprenavir/ ritonavir 700 mg/100 mg twice daily, both with abacavir/lamivudine fixed-dose combination tablet. Primary endpoints were the proportion of subjects achieving HIV-1 RNA

Original language	English
Pages (from-to)	356-367
Number of pages	12
Journal	HIV Clinical Trials
Volume	10
Issue number	6
DOIs	https://doi.org/10.1310/hct1006-356
Publication status	Published - Jan 1 2009

Keywords

Abacavir
Fosamprenavir
HIV
Ritonavir

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)

Access to Document

10.1310/hct1006-356

Cite this

Carosi, G., Lazzarin, A., Stellbrink, H., Moyle, G., Rugina, S., Staszewski, S., Givens, N., Ross, L., Granier, C., Ait-Khaled, M., Leather, D., & Nichols, W. G. (2009). Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects. HIV Clinical Trials, 10(6), 356-367. https://doi.org/10.1310/hct1006-356

Carosi, G, Lazzarin, A, Stellbrink, H, Moyle, G, Rugina, S, Staszewski, S, Givens, N, Ross, L, Granier, C, Ait-Khaled, M, Leather, D & Nichols, WG 2009, 'Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects', HIV Clinical Trials, vol. 10, no. 6, pp. 356-367. https://doi.org/10.1310/hct1006-356

@article{4c3822a4424c43959ef11241e2292cad,

title = "Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-na{\"i}ve HIV-1-infected adult subjects",

abstract = "Purpose: Fosamprenavir/ritonavir 1400 mg/100 mg once-daily regimen may have a more favourable tolerability and lipid profile than the fosamprenavir/ ritonavir twice-daily regimen, while maintaining comparable antiviral efficacy. Methods: This open-label study had a group-sequential design with a stage 1 Week 24 futility analysis, with both efficacy and safety go-criteria for progression to stage 2. There were 214 antiretroviral-naive, HIV-1-infected subjects who were randomised to receive either fosamprenavir/ritonavir 1400 mg/100 mg once daily or fosamprenavir/ ritonavir 700 mg/100 mg twice daily, both with abacavir/lamivudine fixed-dose combination tablet. Primary endpoints were the proportion of subjects achieving HIV-1 RNA ",

keywords = "Abacavir, Fosamprenavir, HIV, Ritonavir",

author = "G. Carosi and A. Lazzarin and H. Stellbrink and G. Moyle and S. Rugina and S. Staszewski and N. Givens and L. Ross and C. Granier and M. Ait-Khaled and D. Leather and Nichols, {W. G.}",

year = "2009",

month = jan,

day = "1",

doi = "10.1310/hct1006-356",

language = "English",

volume = "10",

pages = "356--367",

journal = "HIV Clinical Trials",

issn = "1528-4336",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects

AU - Carosi, G.

AU - Lazzarin, A.

AU - Stellbrink, H.

AU - Moyle, G.

AU - Rugina, S.

AU - Staszewski, S.

AU - Givens, N.

AU - Ross, L.

AU - Granier, C.

AU - Ait-Khaled, M.

AU - Leather, D.

AU - Nichols, W. G.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Purpose: Fosamprenavir/ritonavir 1400 mg/100 mg once-daily regimen may have a more favourable tolerability and lipid profile than the fosamprenavir/ ritonavir twice-daily regimen, while maintaining comparable antiviral efficacy. Methods: This open-label study had a group-sequential design with a stage 1 Week 24 futility analysis, with both efficacy and safety go-criteria for progression to stage 2. There were 214 antiretroviral-naive, HIV-1-infected subjects who were randomised to receive either fosamprenavir/ritonavir 1400 mg/100 mg once daily or fosamprenavir/ ritonavir 700 mg/100 mg twice daily, both with abacavir/lamivudine fixed-dose combination tablet. Primary endpoints were the proportion of subjects achieving HIV-1 RNA

AB - Purpose: Fosamprenavir/ritonavir 1400 mg/100 mg once-daily regimen may have a more favourable tolerability and lipid profile than the fosamprenavir/ ritonavir twice-daily regimen, while maintaining comparable antiviral efficacy. Methods: This open-label study had a group-sequential design with a stage 1 Week 24 futility analysis, with both efficacy and safety go-criteria for progression to stage 2. There were 214 antiretroviral-naive, HIV-1-infected subjects who were randomised to receive either fosamprenavir/ritonavir 1400 mg/100 mg once daily or fosamprenavir/ ritonavir 700 mg/100 mg twice daily, both with abacavir/lamivudine fixed-dose combination tablet. Primary endpoints were the proportion of subjects achieving HIV-1 RNA

KW - Abacavir

KW - Fosamprenavir

KW - HIV

KW - Ritonavir

UR - http://www.scopus.com/inward/record.url?scp=76749143029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749143029&partnerID=8YFLogxK

U2 - 10.1310/hct1006-356

DO - 10.1310/hct1006-356

M3 - Article

C2 - 20133266

AN - SCOPUS:76749143029

SN - 1528-4336

VL - 10

SP - 356

EP - 367

JO - HIV Clinical Trials

JF - HIV Clinical Trials

IS - 6

ER -

Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this